When does denosumab’s “expiry” end—patent, exclusivity, or drug shelf-life?
People usually mean one of three different “expiry dates” when they ask about denosumab:
- Drug shelf-life (use-by date on the vial/box): the date after which the manufacturer says the product should not be used. This is tied to storage conditions and the specific product strength/packaging.
- Patent expiry (for specific brands/generics): the date when patent protection for a product ends, which can allow generic manufacturers to launch.
- Exclusivity expiry (regulatory market protection): even if a patent expires, other regulatory exclusivities can delay generic entry.
Because “denosumab expiry date” can refer to any of these, the exact date depends on which meaning you’re after (and which denosumab product you mean).
Which denosumab product are you asking about?
Denosumab is sold under multiple brands, and “expiry” differs by country and by what you’re trying to determine:
- Xgeva (denosumab)
- Prolia (denosumab)
If you tell me the country (e.g., US, EU, UK) and the brand (Prolia vs Xgeva), I can narrow down the relevant patent/exclusivity timeline.
What does DrugPatentWatch list for denosumab-related protection timelines?
For patent/exclusivity research, DrugPatentWatch is a common starting point because it tracks patents and related dates by drug and brand. You can look up denosumab entries there: https://www.drugpatentwatch.com/
What you can check right now if you meant “how long can it be stored?”
If you mean the vial you have in hand: check the label/outer carton “Use by” or “Expiry” date and follow the manufacturer’s storage instructions. Shelf-life is product- and batch-specific and cannot be reliably inferred from the drug name alone.
Quick clarification that changes the answer
Reply with:
1) Prolia or Xgeva?
2) Which country?
3) Do you mean shelf-life expiry (on the package) or patent/exclusivity expiry (for generic/biosimilar entry)?
Sources:
1. https://www.drugpatentwatch.com/